FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655556> ?p ?o ?g. }

• W4385655556 endingPage "e50042ff" @default.
• W4385655556 startingPage "e50042ff" @default.
• W4385655556 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy and for R/R LBCL within 12 months of first-line chemoimmunotherapy. Cohorts 1 and 2 of the ZUMA-1 study of axi-cel in refractory LBCL showed an objective response rate (ORR) of 83% (complete response [CR] rate, 58%), and Grade ≥3 cytokine release syndrome (CRS) and neurologic events (NEs) were experienced by 11% and 31% of patients, respectively, after ≥2 years median follow-up (Locke et al. Lancet Oncol. 2019). ZUMA-7 (Locke et al. N Engl J Med. 2022) examined axi-cel versus standard of care in patients with R/R LBCL after 1 line of prior therapy and showed efficacy (ORR, 84%; CR rate, 65%) and safety (Grade ≥3 CRS, 6%; Grade ≥3 NEs, 21%) consistent with ZUMA-1 Cohorts 1 and 2. Owing in part to this safety profile, most patients receive commercial axi-cel in an inpatient setting. ZUMA-1 Cohort 6, which evaluated whether improved safety outcomes were observed with prophylactic corticosteroids and earlier use of corticosteroids and/or tocilizumab to manage CRS and NEs, demonstrated no Grade ≥3 CRS and 18% Grade ≥3 NEs with high, durable response rates (ORR, 95%; CR rate, 80%) after ≥2 years median follow-up (Oluwole et al. ASH 2022. #705). Aims: To further advance safety management strategies with axi-cel, ZUMA-24, a Phase 2, open-label, multicenter study, will evaluate the safety and efficacy of axi-cel with prophylactic corticosteroid use in patients with R/R LBCL after 1 prior line of therapy in the outpatient setting. Methods: ZUMA-24 will enroll approximately 40 adult patients with histologically confirmed R/R LBCL who received adequate prior therapy (anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy). Patients will undergo leukapheresis, followed by lymphodepleting chemotherapy (fludarabine/cyclophosphamide) and a single axi-cel infusion (2×106 CAR T cells/kg). Prior to axi-cel infusion on Day 0 and on Days 1 and 2, patients will receive prophylactic dexamethasone at a dose of 10 mg. Patients will undergo daily outpatient monitoring to manage AEs for ≥7 days after axi-cel infusion as set forth by institutional outpatient monitoring program. The primary endpoint is incidence and severity of CRS and NEs. Key secondary endpoints are time to onset and duration of CRS and NEs, rate and duration of hospitalization after axi-cel infusion due to AEs, and measures of efficacy including ORR, CR rate, duration of response, progression-free survival, and overall survival. Additional key inclusion criteria are Eastern Cooperative Oncology Group performance score 0-1 and adherence to prespecified institutional clinical monitoring requirements. Key exclusion criteria include >1 prior line of therapy for LBCL, prior stem cell transplant, and prior anti-CD19 or CAR T-cell therapy. Results: The study is open and actively accruing patients at sites in the United States (NCT05459571). Summary/Conclusion: ZUMA-24 will examine the safety and efficacy of axi-cel with prophylactic corticosteroid use in patients with R/R LBCL after 1 prior line of therapy in the outpatient setting. Keywords: Corticosteroids, CD19, CAR-T, Lymphoma" @default.
• W4385655556 created "2023-08-09" @default.
• W4385655556 creator A5000959540 @default.
• W4385655556 creator A5008419917 @default.
• W4385655556 creator A5012904262 @default.
• W4385655556 creator A5015194203 @default.
• W4385655556 creator A5021087873 @default.
• W4385655556 creator A5023307819 @default.
• W4385655556 creator A5023980350 @default.
• W4385655556 creator A5026503525 @default.
• W4385655556 creator A5035100399 @default.
• W4385655556 creator A5037111172 @default.
• W4385655556 creator A5040504519 @default.
• W4385655556 creator A5051092535 @default.
• W4385655556 creator A5054770306 @default.
• W4385655556 creator A5058757098 @default.
• W4385655556 creator A5071055678 @default.
• W4385655556 creator A5078705613 @default.
• W4385655556 creator A5080153027 @default.
• W4385655556 creator A5082333371 @default.
• W4385655556 date "2023-08-01" @default.
• W4385655556 modified "2023-10-17" @default.
• W4385655556 title "PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING" @default.
• W4385655556 doi "https://doi.org/10.1097/01.hs9.0000976104.50042.ff" @default.
• W4385655556 hasPublicationYear "2023" @default.
• W4385655556 type Work @default.
• W4385655556 citedByCount "0" @default.
• W4385655556 crossrefType "journal-article" @default.
• W4385655556 hasAuthorship W4385655556A5000959540 @default.
• W4385655556 hasAuthorship W4385655556A5008419917 @default.
• W4385655556 hasAuthorship W4385655556A5012904262 @default.
• W4385655556 hasAuthorship W4385655556A5015194203 @default.
• W4385655556 hasAuthorship W4385655556A5021087873 @default.
• W4385655556 hasAuthorship W4385655556A5023307819 @default.
• W4385655556 hasAuthorship W4385655556A5023980350 @default.
• W4385655556 hasAuthorship W4385655556A5026503525 @default.
• W4385655556 hasAuthorship W4385655556A5035100399 @default.
• W4385655556 hasAuthorship W4385655556A5037111172 @default.
• W4385655556 hasAuthorship W4385655556A5040504519 @default.
• W4385655556 hasAuthorship W4385655556A5051092535 @default.
• W4385655556 hasAuthorship W4385655556A5054770306 @default.
• W4385655556 hasAuthorship W4385655556A5058757098 @default.
• W4385655556 hasAuthorship W4385655556A5071055678 @default.
• W4385655556 hasAuthorship W4385655556A5078705613 @default.
• W4385655556 hasAuthorship W4385655556A5080153027 @default.
• W4385655556 hasAuthorship W4385655556A5082333371 @default.
• W4385655556 hasBestOaLocation W43856555561 @default.
• W4385655556 hasConcept C121332964 @default.
• W4385655556 hasConcept C126322002 @default.
• W4385655556 hasConcept C141071460 @default.
• W4385655556 hasConcept C142424586 @default.
• W4385655556 hasConcept C143998085 @default.
• W4385655556 hasConcept C2779338263 @default.
• W4385655556 hasConcept C2780653079 @default.
• W4385655556 hasConcept C2780790343 @default.
• W4385655556 hasConcept C71924100 @default.
• W4385655556 hasConcept C87355193 @default.
• W4385655556 hasConceptScore W4385655556C121332964 @default.
• W4385655556 hasConceptScore W4385655556C126322002 @default.
• W4385655556 hasConceptScore W4385655556C141071460 @default.
• W4385655556 hasConceptScore W4385655556C142424586 @default.
• W4385655556 hasConceptScore W4385655556C143998085 @default.
• W4385655556 hasConceptScore W4385655556C2779338263 @default.
• W4385655556 hasConceptScore W4385655556C2780653079 @default.
• W4385655556 hasConceptScore W4385655556C2780790343 @default.
• W4385655556 hasConceptScore W4385655556C71924100 @default.
• W4385655556 hasConceptScore W4385655556C87355193 @default.
• W4385655556 hasIssue "S3" @default.
• W4385655556 hasLocation W43856555561 @default.
• W4385655556 hasLocation W43856555562 @default.
• W4385655556 hasOpenAccess W4385655556 @default.
• W4385655556 hasPrimaryLocation W43856555561 @default.
• W4385655556 hasRelatedWork W2003938723 @default.
• W4385655556 hasRelatedWork W2047967234 @default.
• W4385655556 hasRelatedWork W2118496982 @default.
• W4385655556 hasRelatedWork W2351796763 @default.
• W4385655556 hasRelatedWork W2364998975 @default.
• W4385655556 hasRelatedWork W2369162477 @default.
• W4385655556 hasRelatedWork W2439875401 @default.
• W4385655556 hasRelatedWork W2567738959 @default.
• W4385655556 hasRelatedWork W4238867864 @default.
• W4385655556 hasRelatedWork W2525756941 @default.
• W4385655556 hasVolume "7" @default.
• W4385655556 isParatext "false" @default.
• W4385655556 isRetracted "false" @default.
• W4385655556 workType "article" @default.